02:14 PM EST, 11/13/2025 (MT Newswires) -- Protagenic Therapeutics ( PTIX ) said Thursday it has completed the enrollment and dosing for its multiple ascending dose phase 1 study evaluating its lead compound PT00114, which targets restoring resilience and balance in individuals suffering from chronic stress and its neurological consequences.

The study, which was conducted in healthy volunteers, is designed to assess the safety and tolerability profile of the treatment following multiple doses over time, the company said.

Protagenic said it expects to finalize and publish top-line results from the study by Nov. 30.

Price: 2.05, Change: +0.13, Percent Change: +6.77